Effects of canrenoate potassium, an aldosterone antagonist on portal hemodynamics in patients with compensated liver cirrhosis

Hepato-Gastroenterology

Volumn 43, Issue 10, 1996, Pages 887-892

  Koda, Masahiko ^a   Murawaki, Yoshikazu ^a   Kawasaki, Hironaka ^a   Ikawa, Shiro ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Aldosterone; Canrenoate potassium; Liver cirrhosis; Portal hemodynamics

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; CANRENOATE POTASSIUM;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD FLOW VELOCITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; FEMALE; HEMODYNAMICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER CIRRHOSIS; MALE; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CANRENOATE POTASSIUM; FEMALE; HEART RATE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PORTAL SYSTEM; ULTRASONOGRAPHY, DOPPLER, DUPLEX;

EID: 0029815750     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Perez-Ayuso RM, Arroyo, V, Planas R, Gaya J, Bory F, Rimola A, Rivera F, Rodes J. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotenic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology 1983; 84:961-968.
2. Angeli P, Pria MD, Bei ED, Albino G, Caregaro L, Merkel C, Ceolotto G, Gatta A. Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology 1994; 10:72-79.
3. Bernardi M, Servadei D, Trevisani F, Rnsticali AG, Gasbarrini G. Importance of plasma aldosterone concentration on the natriuretic effect of spironolactone in patients with liver cirrhosis and ascites. Digestion 1985; 31:189-193.
4. Bernardi M, Gasbarrini G. The renin-angiotensin-aldosterone system in human hepatic cirrhosis. Isr J Med Sci 1986; 22:70-77.
5. Okumura H, Aramaki T, Katsuta Y, Satomura K, Akaike M, Sekiyama, T, Terada H, et al. Reduction in hepatic venous pressure gradient as a consequence of volume contraction due to chronic administration of spironolactone in patients with cirrhosis and no ascites. Am J Gastroenterol 1991; 86:46-5.
6. Garcia-Pagan JC, Salmeron JM, Feu, F Luca A, Gines P, Pizcueta P, Claria J, et al. Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology 1994; 19:1095-1099.
7. Ozaki CF, Anderson JC, Lieberman RP, Rikkers LF. Duplex ultrasonography as a noninvasive technique for assessing portal hemodynamics. Am J Surg 1988; 155:70-75.
8. Cioni G, D'Alimonte P, Zerbinati F, Ventura P, Cristiani A, Vignoli A, Romagnoli R, et al. Duplex-Doppler ultrasonography in the evaluation of cirrhotic patients with portal hypertension and in the analysis of their response to drugs. J Gastroenterol Hepatol 1992; 7:388-392.
9. Lomas DJ, Britton PD, Summerton CB, Seymour CA. Duplex Doppler measurements of portal vein in portal hypertension. Clin Radiol 1993; 48:311-315.
10. Miyazaki M, Higaslrio T, Yamamolo K. Stop-flow analysis of antialdosterone (SC-14266) in the dog. J Osaka City Med Center 1975; 24:277-282.
11. Oka M. Spironolactone inhibits vascular reactivity by a prostaglandin-related mechanism unconnected with aldosterone. Prostagland Med 1981; 7:305-319.
12. Clement DI., Effect of spironolactone on systemic blood pressure, limb blood flow and response to systemic stimulation in hypertensive patients. Eur J Clin Pharmacol 1982; 21:263-267.
13. Yamakado M, Nagano M, Uinezu M, Tagawa H, Kiyose H, Tanaka S. Extrarenal role of aldosterone in the regulation of blood pressure. Am J Hypertens 1988;1:276-279.
14. Schohn DC, Jahn HA, Pelletier BC. Dose-related cardiovascular effects of spironolactone. Am J Cardiol 1993;71:40-45.
15. Zoli M, Marchesini G, Brunori A, Cordiani MR, Pisi E. Portal venous flow in response to acute b-blocker and vasodilatatory treatment in patients with liver cirrhosis. Hepatology 1986; 6:1248-1251.
16. Ohnishi K, Nakayama T, Saito M, Hatano H, Tsukamoto T, Terabayashi H, Sugita S, et al. Effects of propranolol on portal hemodynamics in patients with chronic liver disease. Am J Gastroenterol 1985; 80:132-135.
17. Gaiani S, Bolondi L, Fenyves D, Zironi G, Rigamonti A, Barbara L. Effect of propranolol on portosystemic collateral circulation in patients with cirrhosis. Hepatology 1991;14:824-829.
18. Yang S-S, Ralls PW, Korula J. The effect of oral nitroglycerin on portal blood velocity as measured by ultrasonic Doppler. A double blind. placebo controlled study. J Clin Gastroenterol 1991; 13:173-177.
19. Kimura T, Moriyasu F, Kawasaki T, Someda H, Ono S, Tamada, T, Ymahita Y, et al. Changes in the azygos venous flow evaluated using transesophageal Doppler ultrasound after vasopressin infusion in portal hypertension [Abstract]. Hepatology 1989; 10:579.
20. Bolondi L, Gaiani S, Barbara L. Doppler flowmetry - Clinical applications in portal hypertensive patients. In: Okuda K, Benhamou J-P. eds. Portal hypertension. Clinical and physiolosical aspects. Tokyo: Springer-Verlag, 1991:161-182.